Q-Line Biotech IPO Details
Q-Line Biotech IPO Summary
Q-Line Biotech IPO opens for subscription on 21 May 2026 and closes on 25 May 2026.The IPO will be listed on NSE with the tentative listing date set for 29 May 2026.
Q-Line Biotech IPO price band has been fixed at ₹326 – ₹343 per share. The face value is ₹10 per share with a lot size of 400.
Q-Line Biotech IPO total issue size comprises 62,53,200 shares (aggregating up to ₹214.48 Cr). This includes a fresh issue of 62,53,200 shares (aggregating up to ₹214.48 Cr). Pre-issue shareholding stands at 1,70,74,999, which will increase to 2,33,28,199 post-issue.
Q-Line Biotech IPO carries a ₹112 (32.65%) GMP, reflecting investor sentiment.
Q-Line Biotech IPO Lot Size :Individual Minimum is 2 lots (800 shares) amounting to ₹274,400. Individual Maximum is 2 lots (800 shares) amounting to ₹274,400. SHNI Minimum is 3 lots (1,200 shares) amounting to ₹411,600. SHNI Maximum is 7 lots (2,800 shares) amounting to ₹960,400. BHNI Minimum is 8 lots (3,200 shares) amounting to ₹1,097,600.
Q-Line Biotech IPO Details
Q-Line Biotech IPO Subscription
Q-Line Biotech IPO Application Wise Breakup
Q-Line Biotech IPO Dates
- 21 May 2026Opening dateOpen
- 25 May 2026Closing dateClose
- 26 May 2026Allotment Date Allotment
- 27 May 2026Initiation of RefundsRefund
- 27 May 2026Credit of SharesCredit
- 29 May 2026Listing dateListing
Q-Line Biotech IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual Minimum | 2 | 800 | ₹274,400 |
| Individual Maximum | 2 | 800 | ₹274,400 |
| SHNI Minimum | 3 | 1200 | ₹411,600 |
| SHNI Maximum | 7 | 2800 | ₹960,400 |
| BHNI Minimum | 8 | 3200 | ₹1,097,600 |
Q-Line Biotech IPO Reservation
Promoter Holding
Documents
Q-Line Biotech IPO Valuations
Q-Line Biotech Financial Information
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 561.34 | 455.49 | 339.25 | 251.58 |
| Total Income | 236.50 | 322.58 | 206.45 | 184.81 |
| Profit After Tax | 38.69 | 28.13 | 34.44 | 32.10 |
| EBITDA | 64.23 | 71.32 | 37.63 | 32.98 |
| NET Worth | -0.04 | 189.95 | 161.81 | 127.37 |
| Reserves and Surplus | 2,12,88,920.00 | 188.37 | 160.24 | 125.79 |
| Total Borrowing | 243.85 | 164.95 | 96.91 | 73.65 |
| Amount in ₹ Crore | ||||
About Q-Line Biotech IPO
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, and distribution/supply of diagnostic equipment for different diagnostic healthcare needs.
The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges.
The company's key manufacturing segments include indigenous manufacturing of reagents (Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others [POC Devices & Rapid Tests]) and supplying/manufacturing of in-vitro diagnostics (IVD) and Pathology equipment & devices.
As of December 31, 2025, the total annual capacity was about 1.4 million kits (Haematology, Clinical Chemistry, Rapid/Elisa) and 1,200 Selectra Machines.
As of March 31, 2026, the manufacturing teams include 126 employees and 223 third-party workers collaborating with R&D, supply chain, and external partners to meet benchmarks.
Strength Of Q-Line Biotech IPO
- Established manufacturing capabilities with focus on R&D, Reverse Engineering and quality control.
- Diversified product portfolio with focus on IVD industry.
- Widespread distribution network with a presence across all four regions.
- Long standing relationships with customers.
- Track record of healthy financial performance.
- Experienced Promoter and Management team.
Risk Of Q-Line Biotech IPO
- Any disruption, stoppage, slowdown or shutdown in the company manufacturing facilities or process or research and development activities could adversely affect its business, financial condition, cash flows and results of operations.
- Any delay, interruption or reduction in the supply of its raw materials, trade goods from the company suppliers and manufacturers, or an increase in the costs of such raw materials, trade goods may adversely impact the pricing and supply of its products and have an adverse effect on the company business, financial condition, cash flows and results of operations.
- The company business is dependent on the sale of the company products through distributors which also include its group entity POCT services. The loss of any of these distributors or third parties for any reason may affect the marketing and distribution of the company products adversely and further could impact its business, results of operations, financial conditions and cash flows negatively.
- The company is dependents on certain key suppliers to procure a significant portion of its Raw material for production of reagents and for traded machines. Any denial of supplies or loss of the relationship with them could result in disruption in the company operations, which could have an adverse effect on its business, financial condition, results of operations and cash flows.
- For manufacturing of its machines and reagents, the company is dependent on the agreement with the European companies, any failures to renew the agreement or entering into the agreement on the terms which are not favourable for it may impact the company business operations, financial condition and cash flows.
- The Company has been subject to search and seizure operations by the Income-tax Department and any adverse outcome may adversely affect its financial condition.
- The company operations are concentrated in North India, and any loss of business in such region could have an adverse effect on the company business, results of operations and financial condition.
- The Company requires a significant amount of working capital for continuing growth. Its inability to meet the company working capital requirements may adversely affect its results of operations.
- The company has experienced negative cash flows from operating activities in the last three Fiscal years and may continue to have negative cash flows in the future which could have an impact on its business and operations.
- Fluctuations in interest rates could adversely affect its results of operations.
Objectives Q-Line Biotech IPO
1. To meet Working Capital requirements
2. Repayment of certain borrowing availed by the Company, in part or full
3. General Corporate Purpose
Company Contact Details
Q-Line Biotech Ltd.
298-281,
Transport Nagar,
Kanpur Road Adjacent Transport Nagar Metro Station
Lucknow, Uttar Pradesh, 226012
Phone: +91 522-2435570
Email: compliance@qlinebiotech.com
Website: https://qlinebiotech.com/
Registrar Contact Details
Q-Line Biotech FAQs
The Q-Line Biotech IPO is a SME public issue comprising 6253200 equity shares with a face value of ₹10 each, aggregating to a total issue size of ₹214.48 Cr. The issue price has been fixed at ₹343 per equity share, and the minimum application size is 400 shares.
The IPO opens for subscription on 21 May 2026, and closes on 25 May 2026.
Purva Sharegistry India Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the NSE
As of now, the current GMP stands at ₹112 (32.65%).
Quick Links
Comments
